# A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

> **NCT01449058** · PHASE1 · COMPLETED · sponsor: **Array BioPharma** · enrollment: 139 (actual)

## Conditions studied

- Advanced and Selected Solid Tumors
- AML
- High Risk and Very High Risk MDS

## Interventions

- **DRUG:** BYL719
- **DRUG:** MEK162

## Key facts

- **NCT ID:** NCT01449058
- **Lead sponsor:** Array BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2016-08-31
- **Final completion:** 2017-08-15
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2017-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01449058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01449058, "A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01449058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*